Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 91,705 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 91,705 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the completion of the transaction, the chief executive officer owned 7,229 shares in the company, valued at approximately $956,685.86. The trade was a 92.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Herriot Tabuteau also recently made the following trade(s):

• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total transaction of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The shares were sold at an average price of $134.49, for a total transaction of $2,928,519.75.
• On Tuesday, October 7th, Herriot Tabuteau sold 13,390 shares of Axsome Therapeutics stock. The shares were sold at an average price of $118.77, for a total transaction of $1,590,330.30.
• On Wednesday, October 8th, Herriot Tabuteau sold 12,774 shares of Axsome Therapeutics stock. The shares were sold at an average price of $118.84, for a total transaction of $1,518,062.16.
• On Monday, October 6th, Herriot Tabuteau sold 19,220 shares of Axsome Therapeutics stock. The stock was sold at an average price of $120.17, for a total transaction of $2,309,667.40.
• On Tuesday, September 16th, Herriot Tabuteau sold 19,719 shares of Axsome Therapeutics stock. The stock was sold at an average price of $114.19, for a total transaction of $2,251,712.61.
• On Friday, September 12th, Herriot Tabuteau sold 27,907 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.96, for a total value of $3,319,816.72.
• On Monday, September 15th, Herriot Tabuteau sold 15,254 shares of Axsome Therapeutics stock. The shares were sold at an average price of $117.37, for a total value of $1,790,361.98.

Axsome Therapeutics Stock Up 0.6%

NASDAQ AXSM opened at $135.69 on Thursday. The company has a market capitalization of $6.77 billion, a P/E ratio of -26.76 and a beta of 0.50. The stock has a 50 day moving average price of $124.02 and a 200-day moving average price of $113.19. Axsome Therapeutics, Inc. has a one year low of $75.56 and a one year high of $139.13. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The company had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. The business’s revenue was up 63.2% compared to the same quarter last year. As a group, equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Moors & Cabot Inc. increased its position in Axsome Therapeutics by 4.5% during the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after buying an additional 100 shares during the period. Meridian Wealth Management LLC boosted its position in Axsome Therapeutics by 0.5% during the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock worth $2,687,000 after purchasing an additional 103 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Axsome Therapeutics by 1.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock worth $1,032,000 after purchasing an additional 107 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in Axsome Therapeutics by 6.8% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 2,101 shares of the company’s stock worth $255,000 after purchasing an additional 134 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 0.3% in the first quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock worth $4,621,000 after acquiring an additional 136 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AXSM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada lifted their target price on Axsome Therapeutics from $189.00 to $198.00 and gave the stock an “outperform” rating in a report on Tuesday. Bank of America lifted their price target on Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Needham & Company LLC restated a “buy” rating and issued a $154.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday. Finally, Guggenheim boosted their price objective on Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $180.75.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.